Rasio utang jangka dawa marang modal CRISPR (CRSP)

CRISPR Therapeutics AG (CRSP) is implementing ethical governance standards in gene therapy, minimizing the environmental impact of its corporate operations. Meanwhile, the ecological focus remains secondary, limited to energy efficiency and bio-waste disposal. This price chart demonstrates the metric at 0.46. Business prospects rely on the market launch of Casgevy and advancements in developing modified CAR-T cells to combat cancer.

CRISPR Therapeutics AG (CRSP) is investing colossal funds into the development of gene therapies while facing uncertainty regarding insurance reimbursements and risks of side effects. This metric measures the share of borrowed funds with a maturity of more than one year within the equity structure, allowing for an assessment of the company's financial stability amid capital-intensive research through the ratio of long-term liabilities to equity.